From Morphological Imaging to Molecular Targeting: Implications to Preclinical Development by Markus SchwaigerFrom Morphological Imaging to Molecular Targeting: Implications to Preclinical Development by Markus Schwaiger

From Morphological Imaging to Molecular Targeting: Implications to Preclinical Development

EditorMarkus Schwaiger, Ludger Dinkelborg, Hermann Schweinfurth

Hardcover | June 16, 2004

Pricing and Purchase Info

$193.95

Earn 970 plum® points
Quantity:

In stock online

Ships free on orders over $25

Not available in stores

about

The current progress in molecular medicine allows the identification of a plethora of new and often human-specific drug targets. An early in vivo validation of specific ligands binding to these targets in humans is needed to assess their potential for targeted imaging and radiotherapy. Radiopharmaceuticals are uniquely suitable for such target validation studies. The purpose of the Ernst Schering Research Foundation Workshop 48 was to offer a forum for an open exchange on the state of the art in the early development of such radiopharmaceuticals. Experts from academia, industry and regulatory authorities provided contributions covering the identification of targets, the necessary preclinical studies on the safety of ligands as well as their validation in human clinical trials.
Title:From Morphological Imaging to Molecular Targeting: Implications to Preclinical DevelopmentFormat:HardcoverDimensions:209 pagesPublished:June 16, 2004Publisher:Springer Berlin HeidelbergLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3540201378

ISBN - 13:9783540201373

Look for similar items by category:

Reviews

Table of Contents

M. Schwaiger: Molecular Imaging: Dream or Reality? R. Solari: Target Discovery and Validation; Rudin et al.: Non-Invasive Imaging in Drug Discovery and Development; M.G. Stabin: Internal Dose Assessment - Extrapolation from Animal Species to the Human; Ch. Halldin: Clinical Experience in Human Target Validation in Neurobiology; U. Haberkorn: Future Directions in Molecular Imaging; A. Neil: Regulatory Implications - The EU Perspective; S. Wilson: The FDA Perspective; H. Mayahara: The Japanese Perspective for Radiopharmaceuticals.